Clinical data | |
---|---|
Other names | MXE; 3-MeO-2'-oxo-PCE |
Addiction liability | High[1] |
Drug class | NMDA receptor antagonist; Dissociative hallucinogen; General anesthetic |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 3–6 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H21NO2 |
Molar mass | 247.338 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Methoxetamine (MXE) is a dissociative hallucinogen that has been sold as a designer drug.[5][6] It differs from many dissociatives such as ketamine and phencyclidine (PCP) that were developed as pharmaceutical drugs for use as general anesthetics in that it was designed specifically to increase the antidepressant effects of ketamine.[6][7]
MXE is an arylcyclohexylamine.[8] It acts mainly as an NMDA receptor antagonist, similarly to other arylcyclohexylamines like ketamine and PCP.[8]
pmid23527166
was invoked but never defined (see the help page).